Eisai Building Second Production Facility in Suzhou
April 25, 2013 at 07:22 AM EDT
Eisai, the Japanese biopharma, announced plans to build a new production facility in Suzhou, alongside its current China plant. The new facility will make injectible drugs, especially Methycobal®, a treatment for peripheral neuropathies and one of Eisai’s major products in China. According to Eisai, its China sales are growing, a trend it expects to continue, and the company wants to insure a steady supply of products. More details.... Stock Symbol: (TO: 4523) Share this with colleagues: // //